EU/3/14/1344

About

On 15 October 2014, orphan designation (EU/3/14/1344) was granted by the European Commission to PD Dr med. Joachim Riethmüller, Germany, for nitric oxide for the treatment of cystic fibrosis.

Key facts

Active substance
Nitric oxide
Disease / condition
Treatment of cystic fibrosis
Date of first decision
15/10/2014
Outcome
Positive
EU designation number
EU/3/14/1344

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

PD Dr med. Joachim Riethmüller
Beethovenweg 7
72076 Tübingen
Germany
Tel. +49 7071 298 1442
Fax +49 7071 294 450
E-mail: joachim.riethmueller@med.uni-tuebingen.de

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating